Mohammed Gbadamosi, Ph.D.

Dr. Mohammed Gbadamosi is an Assistant Professor in the Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy.

Dr. Gbadamosi completed his graduate studies Department of Pharmacotherapy and Translational Research at the University of Florida College of Pharmacy. Thereafter, He completed his postdoctoral training as an NIH T32 Postdoctoral Fellow in the Program for Applied Research and Development in Genomic Medicine (PARADIGM) at the University of Florida College of Pharmacy under the mentorship of Dr. Duane Mitchell.

In 2023, Dr. Gbadamosi was selected as one of thirteen individuals to receive the highly prestigious NIH Director’s Early Independence Award. This award enables outstanding junior scientists with the intellect, scientific creativity, drive, and maturity to bypass the traditional postdoctoral training period and launch independent research careers. Dr. Gbadamosi leads a collaborative multidisciplinary research group and his research broadly leverages advanced molecular, cellular, and computational approaches to optimize the efficacy of chemotherapeutic and immuno-oncology agents. His research spans basic and translational sciences with the ultimate end goal of maximizing the efficacy of combinatorial strategies using chemotherapy and immunotherapy (chemoimmunotherapy) and developing curative chemoimmunotherapeutic treatment regimens.

Dr. Gbadamosi’s Early Independence Award study focuses on utilizing multi-omics and machine learning approaches to (1) identify, characterize, and establish the clinical relevance of molecular features that influence chemoimmunomodulation in metastatic triple-negative breast cancer and other types of cancers and (2) construct computational models capable of predicting chemoimmunomodulatory effects using a patient’s baseline molecular profile thus enabling refined methods for personalizing chemoimmunotherapy. Given the poor prognosis and critical health disparities observed in triple-negative breast cancer and the poor efficacy observed from chemoimmunotherapy in triple-negative breast cancer, this study is of critical importance and holds the potential to drastically improve clinical outcomes.

Dr. Gbadamosi also holds membership in the University of Florida Brain Tumor Immunotherapy Program and Preston A. Wells, Jr. Center for Brain Tumor Therapy where he leads studies focused on developing and characterizing models of triple-negative breast cancer brain metastases and their response to chemoimmunotherapy.

Dr. Gbadamosi’s leadership at the University of Florida has driven transformative initiatives, effecting policy changes and fostering academic excellence. His notable contributions include founding the College of Pharmacy Graduate Student Organization, initiating the UF Graduate Education Diversity Champion Award, and serving on the College of Pharmacy Dean’s Leadership Council (2020-2023). Dr. Gbadamosi has a passion for serving the next generation of trainees and students as a mentor, providing advocacy, opportunities, and experiences that enable them to succeed. This includes mentoring undergraduate, graduate, and professional students and actively engages with mentorship-focused programs such as the Maximizing Access to Research Careers (MARC) program. Dr. Gbadamosi is an ad-hoc member of the Gene Regulation in Cancer NIH Study Section, is a Fellow of the Cancer Research Education and Engagement (CaRE2) Health Equity Center, and contributes as a reviewer for esteemed journals.